0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TrkB

TrkB

Brief Information

Name:Neurotrophic tyrosine kinase receptor type 2
Target Synonym:EC 2.7.10,EC:2.7.10.1,Tropomyosin-related kinase B,Trk-B,GP145-TrkB,NTRK2,Neurotrophic Tyrosine Kinase Receptor Type 2,TRKB,BDNF-Tropomyosine Receptor Kinase B,BDNF/NT-3 Growth Factors Receptor,Tyrosine Kinase Receptor B,TrkB Tyrosine Kinase,EC 2.7.10.1,O
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
NT2-H5228 Human Human TrkB / NTRK2 Protein, His Tag
NT2-H5228-structure
NT2-H5228-sds
NT2-H5254 Human Human TrkB / NTRK2 Protein, Fc Tag
NT2-H5254-structure
NT2-H5254-sds

Synonym Name

NTRK2,TRKB,GP145-TrkB

Background

Neurotrophic tyrosine kinase receptor type 2 (NTRK2) is also known as BDNF/NT-3 growth factors receptor, Tropomyosin-related kinase B (TRKB) and TrkB tyrosine kinase, which belongs to the protein kinase superfamily or Tyr protein kinase family. Insulin receptor subfamily. NTRK2 / TrkB contains two Ig-like C2-type (immunoglobulin-like) domains, two LRR (leucine-rich) repeats, one LRRCT domain, one LRRNT domain, one protein kinase domain. NTRK2 / Trk-B is expressed in the central and peripheral nervous system. The catalytic activity of NTRK2 is ¡°ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate¡±. NTRK2 / TrkB involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Cabozantinib S-malate BMS-907351; XL-184 Approved Exelixis Inc Cometriq, Cabometyx Japan Carcinoma, Renal Cell s:6:"Takeda"; 2012-11-29 Solid tumours; Pain; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Glioblastoma; Kidney Diseases; Prostatic Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Thyroid Neoplasms; Carcinoma, Neuroendocrine; Lymphoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Larotrectinib sulfate ARRY-470; LOXO-101 Approved Array Biopharma Vitrakvi Japan Solid tumours s:17:"Bayer Yakuhin Ltd"; 2018-11-26 Solid tumours; Neoplasms Details
Entrectinib NMS-E628; RXDX-101; RG-6268 Approved Nerviano Medical Sciences Rozlytrek EU Solid tumours; Carcinoma, Non-Small-Cell Lung s:23:"Roche Registration Gmbh"; 2019-06-18 Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Thyroid Cancer, Papillary; Melanoma; Lymphoma, Large-Cell, Anaplastic; Hepatic Insufficiency; Colorectal Neoplasms; Sarcoma; Cholangiocarcinoma; Solid tumours; Brain Neoplasms; Neuroendocrine Tumors; Central Nervous System Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Head and Neck Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ACD-856 ACD-856 Phase 1 Clinical Alzecure Pharma Ab Alzheimer Disease Details
PLX-7486 PLX-7486; PLX7486-TsOH Phase 1 Clinical Daiichi Sankyo Co Ltd Giant Cell Tumor of Tendon Sheath; Solid tumours; Pancreatic Neoplasms Details
BN-201 BN-201 Phase 1 Clinical Bionure Optic Neuritis; Demyelinating Diseases; Neuromyelitis Optica Details
HG-030 HG-030 Phase 1 Clinical Hitgen Inc Solid tumours Details
Repotrectinib TPX-0005 Phase 3 Clinical Turning Point Therapeutics Solid tumours; Central Nervous System Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung Details
Lestaurtinib SP-924; CEP-701; KT-5555; SPM-924; A-154475.0 Phase 3 Clinical Kyowa Hakko Kirin Leukemia, Myeloid; Bone Marrow Neoplasms; Polycythemia Vera; Prostatic Neoplasms; Psoriasis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Thrombocythemia, Essential Details
Altiratinib DP-5164; DCC-2701; DCC-22701; T-678746713 Phase 1 Clinical Deciphera Solid tumours; Neoplasms Details
Taletrectinib DS-6051b; DS-6051a; DS-6051; AB-106 Phase 2 Clinical Daiichi Sankyo Co Ltd Solid tumours; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop